Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
10
77%
Ph phase_1
3
23%

Phase Distribution

3

Early Stage

10

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
10(76.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(9)
Terminated(1)
Other(2)

Detailed Status

Completed9
unknown2
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (23.1%)
Phase 210 (76.9%)

Trials by Status

completed969%
unknown215%
withdrawn18%
not_yet_recruiting18%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_2

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

NCT04312594
withdrawnphase_2

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

NCT05702788
not_yet_recruitingphase_2

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

NCT04971551
completedphase_1

A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers

NCT06246695
completedphase_1

Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

NCT04993404
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT04312594Phase 2

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

Completed
NCT05702788Phase 2

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

Withdrawn
NCT04971551Phase 2

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Not Yet Recruiting
NCT06246695Phase 1

A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers

Completed
NCT04993404Phase 1

Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

Completed
NCT06132243Phase 1

Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions

Completed
NCT04851535Phase 2

Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Completed
NCT05686629Phase 2

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Unknown
NCT05688839Phase 2

A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Unknown
NCT04217993Phase 2

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Completed
NCT04507659Phase 2

Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis

Completed
NCT04034134Phase 2

Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

Completed
NCT03886415Phase 2

Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13